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The Way to Determine
Coenzyme Q
Coenzyme Q (CoQ, ubiquinone) is a lipophilic molecule present
in all cells, located mainly in the inner mitochondrial membrane.
It is composed of a redox active benzoquinone ring conjugated to
an isoprenoid chain. The length of the chain differs among species;
in humans, it contains predominantly 10 isoprenoid units (CoQ10).
The synthesis of this chain shares the mevalonate pathway with
cholesterol and dolichol biosynthesis (1), in which 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-Co A) reductase is a key
enzyme and target for statins. CoQ shuttles electrons from com-
plex I and complex II, to complex III of the mitochondrial respi-
ratory chain. It also functions as a lipid-soluble antioxidant, and is
involved in multiple aspects of cellular metabolism, including
pyrimidine nucleotide biosynthesis and beta-oxidation of fatty
acids (1).
Recently, Larsen et al. (2) studied the role of simvastatin on
skeletal muscle of patients with hypercholesterolemia. This
work indicates that simvastatin compromises glucose intolerance
and decreases insulin sensitivity, and also indicates a decrease of
coenzyme Q10 (CoQ10) in human skeletal muscle. However, these
results are based on an analytical mistake because the authors have
confused the lipid antioxidant CoQ10 with the encoded protein by
the COQ10B gene. COQ10B encodes for a mitochondrial protein
that does not participate in CoQ10 biosynthesis and apparently
contributes to CoQ10 function in respiration (3).
Their paper claims the changes of CoQ10 are caused by sim-
vastatin, but the authors have analyzed the expression of Coq10b
peptide using the antibody ab41997 (Abcam, Cambridge, United
Kingdom), included in their Figure 6, that should not be confusedwith the lipid CoQ10 content. The analysis of CoQ10 is carried
out in hexane-ethanol extracts by a high-performance liquid
chromatography system with a C18 reversed-phase column and
an electrochemical detector (4). This approach has previously
demonstrated that statin drug–related myopathy is associated with
a mild decrease in muscle CoQ10 concentration (5). The overall
work of Larsen et al. (2) is not invalidated by this comment, but the
results on CoQ10 levels should be revised.*Plácido Navas, PhD
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statin-related myopathy. Arch Neurol 2005;62:1709–12.ReplyWe appreciate the comment from Dr. Navas regarding our recent
report on simvastatin’s effect on skeletal muscle (1).
We agree with Dr. Navas that the coenzyme Q–binding protein
COQ10 homolog B (COQ10B) was measured. As Dr. Navas
writes in his letter, COQ10B is essential to the function of coen-
zyme Q10 (CoQ10) in regard to mitochondrial respiration (1). In
a paper by Barros et al. (2), it is suggested that COQ10B in yeast is
binding coenzyme Q6 (CoQ6), which is necessary for CoQ6 to
transport electrons in the electron transport chain, which subse-
quently leads to the transport of electrons and production of ATP
(2). CoQ6 is present in yeast and bacteria, and is equivalent to
CoQ10 in humans (3). Previously, it has been reported that statin
treatment decreases the amount of CoQ10 in skeletal muscle (4),
and in combination with the results from our present report
observing a reduced content of COQ10B (1), this indicates that
statin treatment has a similar effect on CoQ10 and COQ10B.
COQ10B is essential for electron transport in the mitochondrial
electron transport chain, and therefore, we believe that our conclusion
in the report is valid, as Dr. Navas also writes in his letter.*Steen Larsen, MSci
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Arterial Stiffness
Die Methode ist Alles
We are concerned about methods used by our esteemed colleagues,
Coutinho et al. (1), and question their conclusion, based on higher
characteristic impedance (Zc) and lower total arterial compliance
(TAC), that the aorta and large elastic arteries of women are stiffer
than those of men. Both calculated Zc and TAC relate volume to
pressure without scaling. The aorta of a child is small. With
growth, Zc decreases and TAC increases, but this cannot be
interpreted as lower stiffness because arteries become more, not
less, stiff with age (2). Likewise, small animals have higher Zc and
lower TAC than larger animals. Because there are systematic
differences in weight and height between male and female adult
cohorts (2), the (smaller) females will appear to have stiffer arteries
(i.e., higher Zc and lower TAC) than men if not appropriately
scaled for body size. When appropriately scaled to aortic cross-
sectional area in Table 1 of Coutinho et al. (1), Zc in males
(172  10 cm2 ¼ 1,720 dynes $ s $ cm3) and in females (211 
8.3 ¼ 1,751 dynes $ s $ cm3) are virtually identical. With the same
scaling, TAC also appears identical.
Scaling is used elsewhere in the authors’ data analysis, but not
consistently. Smaller echo dimensions in females are consistent
with smaller body size (Table 1 [1]). Height and weight are not
provided in the table, text, or online appendix.
The authors’ Table 1 (1) contains many anomalies that ought be
considered and explained. Ampliﬁcation of the pressure wave
between the central and peripheral sites is 3%, not 5%, in males,
and 3%, not zero, in females. Both values are much lower than
measured invasively (2). Mean pressure, calculated as (brachial dia-
stolic blood pressure  2 þ systolic blood pressure) O 3 (data
supplement [1]), is 93, not 97, mmHg for males and 92, not 98, mm
Hg for females. Values for left ventricular (LV) outﬂow tractdiameter must be centimeters, not millimeters (i.e., 2.3 cm male,
2.0 cm female). Taper in diameter of 55% in males (35.6/23.0) and
63% for females (32.6/20.0) over a length of <5 cm between the
LV outﬂow tract and site of aortic diameter measurement (which
we do not challenge) must create secondary ﬂow and turbulence in
the aorta (2). There is concern also on the low value of pressure
ampliﬁcation compared with those in the authors’ reference 9 (1)
and in the paper by Safar et al. (3) in the same issue of the Journal.
The authors are highly respected clinical investigators and
colleagues, and may not be aware of the aforementioned anomalies,
if their data were analyzed in an outside center without adequate
technical scrutiny. We have not been able to trace the source of the
quoted “NIHem” on the Internet. We need stress in papers such as
this, Carl Ludwig’s dictum: “Die Methode ist Alles” (2).
Differences in arterial hemodynamics between adult males and
females do exist, but can be attributed to shorter body length with
earlier return of wave reﬂection, and hence, greater aortic pressure
augmentation in females (the authors’ Table 1). Such greater
pressure augmentation accounts for impaired LV relaxation and the
higher prevalence of diastolic heart failure in females (2). In this,
we certainly agree.*Michael F. O’Rourke, DSc
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Cardiol 2013;61:12–9.ReplyWe thank Drs. O’Rourke and Safar, on behalf of all the authors, for
their interest in our paper (1). They highlight the importance of
“scaling” for aortic size, given the known inverse relationship
between aortic diameter and characteristic impedance (Zc) (2). The
multivariable models presented in our study (1) adjusted for aortic
diameter as a measure of body size and demonstrated that women
had higher Zc even after adjusting for aortic size. The augmenta-
tion index (AIx) was indeed higher in women than men in
our study, but was not associated with left ventricular diastolic
function or ventricular–arterial coupling. In our cohort of older,
predominantly hypertensive participants, increased proximal aortic
